RESUMEN
The heterogeneity in the plasma of peptide hormones has been known for some time. The demonstration of various fragments of circulating parathormone was undertaken using two antisera, which permitted the authors to study: -- the plasma half-life of parathormone; -- the variations in parathormone levels during dynamic tests; -- the limits between normal and pathological levels. It was thus demonstrated that the antisera recognised, in one case, the terminal carboxyl fragment, in the other case, the terminal amino fragment.
Asunto(s)
Hormona Paratiroidea/sangre , Reacciones Antígeno-Anticuerpo , Semivida , Humanos , Hormona Paratiroidea/inmunología , Fragmentos de Péptidos , Conformación Proteica , RadioinmunoensayoRESUMEN
Multisite cervico-mediastinal venous blood samples were collected fort the estimation of parathormone before operation in twenty four patients subsequently confirmed at surgery to have primary hyperparathyroidism. The examination made it possible to lateralise a single (single adenoma: 18 cases) or predominant lesion (multiple adenomas or hyperplasia: 6 cases), in 15 of them (62%). In patients with a single adenoma, exact lateralisation was obtained in 12 out of 18 cases (9 had selective samples with 7 accurate lateralisations). This lengthy and costly examination is essentially of value in localisation and should be used essentially in patients with virtually definite primary hyperparathyroidism and in whom the responsible lesion has not been discovered at exploratory operation.
Asunto(s)
Recolección de Muestras de Sangre/métodos , Hiperparatiroidismo/sangre , Hormona Paratiroidea/sangre , Calcio/sangre , Cateterismo , Diagnóstico Diferencial , Humanos , Hiperparatiroidismo/etiología , Venas Yugulares , Neoplasias del Mediastino/diagnóstico , Mediastino/irrigación sanguínea , Flebografía , Radioinmunoensayo , Timo/irrigación sanguínea , Glándula Tiroides/irrigación sanguínea , VenasRESUMEN
Four microgrammes of 1-alpha-hydroxycholecalciferol (1-alpha-OH D3) or 200 mug of 25-hydroxycholecalciferol (25-OH D3) were given orally every other day respectively to 10 uraemic patients (8 on chronic haemodialysis) for 1-12 weeks and to 3 patients on chronic haemodialysis for 4-8 weeks. A transilial bone biopsy and serial evaluation of serum immunoreactive PTH (iPTH) calcium phosphate and alkaline phosphatase were performed before and at the end of therapy. Both 1-alpha-OH D3 and 25-OH D3 (the latter at a 50 times higher dose) were able to depress hyperparathyroidism in two-thirds of the cases and to consistently improve the mineralisation defect. In no case did iPTH or the bone histomorphometric parameters return to normal, so that long term evaluation of these two drugs is warranted.